Clinical Trials Logo
  1. Home
  2. Neutropenia, Febrile
  3. NCT03511820

A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever

Neutropenia, Febrile Clinical Trial

Official title:
A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever

Clinical Trial Summary

Amphotericin B is a polyene antifungal drug used for the treatment of many systemic fungal infections. It is associated with many side effects which in some cases can be very severe and potentially lethal. Lipo-AB® is a true single bilayer liposomal drug delivery system, consisting of unilamellar bilayer liposomes with amphotericin B intercalated within the membrane. Prior studies showed that the liposomal formulation of amphotericin B greatly reduces the side effects of the parent drug, such as nephrotoxicity. This study is designed to evaluate the safety and efficacy of Lipo-AB® in neutropenic patients with persistent fever in routine clinical practice in Taiwan.

1. Primary objective:

• To evaluate the nephrotoxicity of Lipo-AB® (amphotericin B) treatment in neutropenic patients with persistent fever in Taiwan clinical practice.

2. Secondary objectives:

(1) To evaluate the safety profile of Lipo-AB® (amphotericin B) in neutropenic patients with persistent fever in Taiwan clinical practice.

(2) To evaluate the treatment efficacy of Lipo-AB® (amphotericin B) in neutropenic patients with persistent fever in Taiwan clinical practice.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03511820
Study type Observational
Source TTY Biopharm
Contact
Status Completed
Phase
Start date May 24, 2016
Completion date January 15, 2018
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04637464 - Early Termination of Empirical Antibiotics in Febrile Neutropenia in Children With Cancer N/A
Not yet recruiting NCT04260230 - Remote Monitoring of Patients at Risk of Sepsis N/A
Completed NCT04187755 - Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever Phase 4
Completed NCT03217721 - Antibiotics Management of Septic Neutropenic Patients in the Intensive Care Unit N/A
Completed NCT04669418 - Host RNA Signature in Children With Cancer and Infection
Recruiting NCT04938206 - DIStinguishing ChildrEn at Low Risk of Severe infectioN in Case of Febrile Neutropenia-7: Impact Study of a Clinical Decision Rule N/A
Terminated NCT03003273 - Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study Phase 3
Recruiting NCT05926063 - Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia Phase 4
Not yet recruiting NCT05852249 - Investigation of the Usability of Neutrocheck Amongst Healthy Volunteers and Healthcare Professionals.
Withdrawn NCT05061654 - CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients Phase 4
Recruiting NCT02474550 - Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma N/A